Altimmune Depreciation And Amortization from 2010 to 2024

ALT Stock  USD 7.27  0.09  1.22%   
Altimmune Depreciation And Amortization yearly trend continues to be comparatively stable with very little volatility. Depreciation And Amortization will likely drop to about 453.1 K in 2024. Depreciation And Amortization is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. View All Fundamentals
 
Depreciation And Amortization  
First Reported
2005-09-30
Previous Quarter
-552 K
Current Value
1.9 M
Quarterly Volatility
344.5 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Altimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Altimmune main balance sheet or income statement drivers, such as Interest Expense of 33.2 K, Selling General Administrative of 13.5 M or Total Revenue of 404.7 K, as well as many exotic indicators such as Price To Sales Ratio of 1.5 K, Dividend Yield of 0.0 or PTB Ratio of 3.24. Altimmune financial statements analysis is a perfect complement when working with Altimmune Valuation or Volatility modules.
  
This module can also supplement Altimmune's financial leverage analysis and stock options assessment as well as various Altimmune Technical models . Check out the analysis of Altimmune Correlation against competitors.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

Latest Altimmune's Depreciation And Amortization Growth Pattern

Below is the plot of the Depreciation And Amortization of Altimmune over the last few years. It is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. Altimmune's Depreciation And Amortization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Altimmune's overall financial position and show how it may be relating to other accounts over time.
Depreciation And Amortization10 Years Trend
Slightly volatile
   Depreciation And Amortization   
       Timeline  

Altimmune Depreciation And Amortization Regression Statistics

Arithmetic Mean1,355,779
Geometric Mean488,214
Coefficient Of Variation209.30
Mean Deviation1,628,721
Median453,150
Standard Deviation2,837,640
Sample Variance8.1T
Range11.1M
R-Value0.34
Mean Square Error7.6T
R-Squared0.12
Significance0.21
Slope218,817
Total Sum of Squares112.7T

Altimmune Depreciation And Amortization History

2024453.1 K
2023477 K
20222.8 M
202111.2 M
2020644.7 K
20192.2 M
2018302.4 K

About Altimmune Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Altimmune income statement, its balance sheet, and the statement of cash flows. Altimmune investors use historical funamental indicators, such as Altimmune's Depreciation And Amortization, to determine how well the company is positioned to perform in the future. Although Altimmune investors may use each financial statement separately, they are all related. The changes in Altimmune's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Altimmune's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Altimmune Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Altimmune. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Depreciation And Amortization477 K453.1 K

Pair Trading with Altimmune

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.

Moving together with Altimmune Stock

  0.73XCUR ExicurePairCorr

Moving against Altimmune Stock

  0.55ELYM Eliem Therapeutics TrendingPairCorr
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Altimmune is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Altimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Altimmune Stock. Highlighted below are key reports to facilitate an investment decision about Altimmune Stock:
Check out the analysis of Altimmune Correlation against competitors.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Altimmune Stock analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.66)
Revenue Per Share
0.008
Quarterly Revenue Growth
180
Return On Assets
(0.25)
Return On Equity
(0.47)
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.